Lewes, DE -- (SBWIRE) -- 08/08/2018 -- Fatty Acid Amide Hydrolase (FAAH) Inhibitors- Pipeline Insights, 2018 report outlays comprehensive insights of present scenario and growth prospects across Fatty Acid Amide Hydrolase (FAAH) Inhibitor. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type. This report provides detailed analysis of 5+ active products with more than 5 companies involved. Two of the key players include PF-04457845 of Spring Works Therapeutics and JNJ-42165279 of Janssen.

Products covered by Phase
- Phase II
- Pre-clinical
- Inactive (Dormant and Discontinued)

Overview of pipeline development activities for Fatty Acid Amide Hydrolase (FAAH) Inhibitors
Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details.

Therapeutic segmentation of products for Fatty Acid Amide Hydrolase (FAAH) Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.

Methodology
Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by Publisher's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope of the report
- Provides an overview of therapeutic pipeline activity for Fatty Acid Amide Hydrolase (FAAH) Inhibitors across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Fatty Acid Amide Hydrolase (FAAH) Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information
- Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
- Coverage of dormant and discontinued pipeline projects across Fatty Acid Amide Hydrolase (FAAH) Inhibitors

Reasons to Buy
- Establish a comprehensive understanding of the current pipeline scenario across Fatty Acid Amide Hydrolase (FAAH) Inhibitors to formulate effective R&D strategies
- Assess challenges and opportunities that influence Fatty Acid Amide Hydrolase (FAAH) Inhibitors R&D
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Identify the relationship between the products and use it for target finding, drug repurposing, and precision medicine
- Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Fatty Acid Amide Hydrolase (FAAH) Inhibitors to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive and discontinued drugs

Spanning over 85 pages "Fatty Acid Amide Hydrolase (FAAH) Inhibitors- Pipeline Insights, 2018" report covers Executive Summary, Overview, Introduction, Fatty acid amide hydrolase (FAAH) Inhibitor, Pipeline Therapeutics (Active Products), Pipeline Therapeutics (Inactive Products), Comparative Analysis, Product Description, Research and Development, Appendix. This report Covered Companies few are - Exxel Phrma, Janssen, MAKscientific, Pfizer, Scythian Biosciences, Bial pharmaceuticals, Infinity Pharmaceuticals, Iron wood pharma, Johnson and johnson, Leadiant Biosciences, Makscientific.

Please visit this link for more details: https://www.marketresearchreports.com/delveinsight/fatty-acid-amide-hydrolase-faah-inhibitors-pipeline-insights-2018

Find all Drug Pipeline Reports at: https://www.marketresearchreports.com/drug-pipeline

Read our Interactive Market Research Blog

About MarketResearchReprots.com
MarketResearchReprots.com is world's largest store offering quality market research, SWOT analysis, competitive intelligence and industry reports. We help Fortune 500 to Start-Ups with the latest market research reports on global & regional markets which comprise key industries, leading market players, new products and latest industry analysis & trends.

Contact us for your market research requirements: https://www.marketresearchreports.com/contact